| Literature DB >> 35402521 |
Jiatian Li1, Yajuan Lin1, Han Li1, Rui Fan1, Li Lin1, Xinying Wang1, Yinong Jiang2, Yun-Long Xia2, Bo Zhang2, Xiaolei Yang1.
Abstract
Background: This study explored the relationship between the TyG index/serum uric acid (SUA) panel and myocardial revascularization (MRT) for new-onset acute coronary syndromes (ACS).Entities:
Keywords: TyG index; acute coronary syndromes; coronary artery disease; myocardial revascularization; serum uric acid
Year: 2022 PMID: 35402521 PMCID: PMC8987771 DOI: 10.3389/fcvm.2022.862252
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
FIGURE 1The flow chart of this cohort study.
Baseline clinical characteristics of patients in different triglyceride-glucose (TyG) index groups.
| Variables | TyG < 8.41 mg/dl | 8.41 ≤ TyG < 8.80 mg/dl | 8.80 ≤ TyG < 9.25 mg/dl | TyG ≥ 9.25 mg/dl | |
| Age (year) | 61.04 ± 9.18 | 62.07 ± 8.61 | 62.51 ± 9.02 | 63.21 ± 10.74 | <0.001 |
| Male, | 2,322 (70.0%) | 2,375 (71.5%) | 2,324 (73.0%) | 2,422 (73.0%) | 0.035 |
| SBP (mmHg) | 128.50 (118.0, 145.0) | 131.8 (118.0, 150.0) | 136.9 (119.0, 155.0) | 139.0 (120.0, 156.0) | 0.038 |
| BMI (kg/m2) | 26.16 ± 3.68 | 26.17 ± 3.69 | 26.24 ± 3.70 | 26.95 ± 3.73 | 0.048 |
| LDL-C (mmol/L) | 2.44 (1.86, 2.96) | 2.45 (1.87, 2.95) | 2.46 (1.88, 2.96) | 2.50 (1.87, 2.98) | 0.191 |
| TC (mmol/L) | 4.02 (3.37, 4.87) | 4.27 (3.58, 5.08) | 4.47 (3.73, 5.32) | 5.33 (4.09, 6.08) | <0.001 |
| HDL-C (mmol/L) | 1.00 (0.91,1.28) | 1.05 (0.90, 1.66) | 1.15 (0.90, 1.86) | 1.19 (1.10, 2.24) | <0.001 |
| LP(a) (mmol/L) | 161.0 (85.0, 309.0) | 161 (86.0, 312.7) | 156.8 (86.5, 299.0) | 160.60 (87.0, 305.9) | 0.96 |
| TG (mmol/L) | 0.84 (0.70, 0.99) | 1.28 (1.11,1.46) | 1.79 (1.46, 2.09) | 2.81 (2.04, 4.09) | <0.001 |
| FPG (mmol/L) | 4.94 (4.57, 5.40) | 5.25 (4.79, 5.96) | 5.61 (4.98, 6.91) | 6.68 (5.23, 9.72) | <0.001 |
| SUA (mmol/L) | 305.3 (269.0, 398.0) | 326.5 (271.0, 406.0) | 348.1 (285.0, 423.0) | 355.8 (289.0, 440.0) | <0.001 |
| Creatinine (mmol/L) | 69.00 (59.86, 79.00) | 71.24 (60.00, 79.00) | 72.60 (60.01, 80.00) | 72.88 (61.0, 81.0) | 0.046 |
| WBC (10∧9/L) | 6.49 (5.26, 8.06) | 6.81 (5.60, 8.41) | 6.86 (5.56, 8.57) | 7.56 (5.68, 8.86) | <0.001 |
| Platelet (10∧9/L) | 198.0 (164.0, 242.7) | 203.0 (169.0, 243.0) | 214.0 (173.0, 246.0) | 218.6 (178.0, 251.0) | 0.005 |
| RBC (10∧9/L) | 4.00 (4.14, 4.79) | 4.05 (4.15, 4.90) | 4.35 (4.15, 4.99) | 4.59 (4.17, 5.10) | <0.001 |
| Current smoker, | 1,410 (42.5%) | 1,378 (41.5%) | 1,378 (41.5%) | 1,337 (40.3%) | 0.042 |
| Current drinker, | 760 (22.9%) | 731 (22.0%) | 737 (22.2%) | 666 (20.1%) | 0.009 |
| Statin use, | 2,801 (84.6%) | 2,766 (83.3%) | 2,752 (83.0%) | 2,770 (83.5%) | 0.197 |
| HTN, | 1,236 (37.3%) | 1,529 (46.0%) | 1,628 (49.1%) | 1,665 (50.2%) | <0.001 |
| Diabetes, | 309 (9.3%) | 560 (16.9%) | 888 (26.8%) | 1,456 (43.9%) | <0.001 |
| MRT, | 1,772 (53.5%) | 2,044 (61.5%) | 2,155 (65.0%) | 2,230 (67.2%) | <0.001 |
|
| |||||
| LCA, | 295 (8.9%) | 343 (10.3%) | 368 (11.1%) | 370 (11.2%) | 0.001 |
| LAD, | 2,124 (64.1%) | 2,336 (70.3%) | 2,403 (72.4%) | 2,502 (75.4%) | <0.001 |
| LCX, | 1,555 (46.9%) | 1,626 (49.0%) | 1,822 (54.9%) | 1,928 (58.1%) | <0.001 |
| RCA, | 1,791 (54.0%) | 1,979 (59.6%) | 2,073 (62.5%) | 2,129 (64.2%) | <0.001 |
BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; MRT, myocardial revascularization; RBC, red blood cell count; SBP, systolic blood pressure; SUA, serum uric acid; WBC, white blood cell count; TC, total cholesterol; TG, triglyceride; LCA, left coronary artery; LAD, left anterior descending; LCX, left circumflex artery; RCA, right coronary artery.
The risk estimate for the myocardial revascularization based on the TyG quartiles.
| Q1 | Q2 | Q3 | Q4 | ||
|
| |||||
| Myocardial revascularization, | 1,772 (53.5%) | 2,044 (61.5%) | 2,155 (65.0%) | 2,230 (67.2%) | |
| Model 1 | Ref. | 1.31 (1.18, 1.45) | 1.57 (1.42, 1.74) | 2.08 (1.87, 2.31) | <0.001 |
| Model 2 | Ref. | 1.18 (1.05, 1.33) | 1.30 (1.16, 1.47) | 1.55 (1.37, 1.75) | |
|
| |||||
| Myocardial revascularization, | 1,281 (55.2%) | 1,476 (62.1%) | 1,513 (65.1%) | 1,617 (66.8%) | |
| Model 1 | Ref. | 1.25 (1.11, 1.41) | 1.48 (1.31, 1.68) | 1.90 (1.68, 2.15) | <0.001 |
| Model 2 | Ref. | 1.12 (1.01, 1.28) | 1.26 (1.10, 1.46) | 1.45 (1.25, 1.68) | |
|
| |||||
| Myocardial Revascularization, | 491 (49.4%) | 568 (60.0%) | 642 (64.7%) | 613 (68.4%) | |
| Model 1 | Ref. | 1.48 (1.12,1.80) | 1.81 (1.49, 2.20) | 2.57 (2.09, 3.17) | <0.001 |
| Model 2 | Ref. | 1.31 (1.05, 1.64) | 1.37 (1.06, 1.68) | 1.59 (1.23, 2.06) | |
BMI, body mass index; HDL-C, high density lipoprotein cholesterol; PLT, platelets; RBC, red blood cell count; SBP, systolic blood pressure; SUA, serum uric acid; WBC, white blood cell count; TC, total cholesterol.
The risk estimate for the myocardial revascularization based on the UA quartiles.
| Q1 | Q2 | Q3 | Q4 | ||
|
| |||||
| Myocardial revascularization, | 2,487 (70.9%) | 2,223 (61.8%) | 2,061 (58.2%) | 2,047 (57.2%) | |
| Model 1 | Ref. | 0.68 (0.61,0.76) | 0.61 (0.55,0.68) | 0.58 (0.52,0.64) | <0.001 |
| Model 2 | Ref. | 0.76 (0.68,0.86) | 0.63 (0.51,0.70) | 0.57 (0.51,0.64) | |
|
| |||||
| Myocardial revascularization, | 1,691 (72.0%) | 1,556 (61.2%) | 1,531 (59.3%) | 1,557 (58.2%) | |
| Model 1 | Ref. | 0.64 (0.57,0.74) | 0.62 (0.55,0.70) | 0.59 (0.52,0.69) | <0.001 |
| Model 2 | Ref. | 0.61 (0.53,0.69) | 0.60 (0.47,0.68) | 0.58 (0.51,0.70) | |
|
| |||||
| Myocardial revascularization, | 796 (68.6%) | 667 (63.0%) | 530 (55.2%) | 490 (54.0%) | |
| Model 1 | Ref. | 0.77 (0.64,0.93) | 0.56 (0.46,0.68) | 0.52 (0.43,0.64) | <0.001 |
| Model 2 | Ref. | 0.68 (0.59,0.88) | 0.50 (0.44,0.67) | 0.47 (0.32,0.65) | |
BMI, body mass index; HDL-C, high density lipoprotein cholesterol; PLT, platelets; RBC, red blood cell count; SBP, systolic blood pressure; SUA, serum uric acid; WBC, white blood cell count; TC, total cholesterol.
FIGURE 2The risk of myocardial revascularization (MRT) in new-onset acute coronary syndromes (ACS) patients based on baseline triglyceride-glucose (TyG) index quartiles. Adjusted odds ratios (ORs) for MRT in: (A) SUA-quartiles 1; (B) SUA-quartiles 2; (C) SUA-quartiles 3; and (D) SUA-quartiles 4. (E) Absolute risk for MRT in each group based on the TyG index quartiles and SUA quartiles.
FIGURE 3The risk of MRT in males and females based on baseline TyG index quartiles. Adjusted ORs for MRT in males in: (A) SUA-quartiles 1; (B) SUA-quartiles 2; (C) SUA-quartiles 3; and (D) SUA-quartiles 4. Adjusted ORs for MRT in females in: (E) SUA-quartiles 1; (F) SUA-quartiles 2; (G) SUA-quartiles 3; and (H) SUA-quartiles 4.
FIGURE 4Absolute risk of MRT by TyG index and SUA quartiles for new-onset ACS patients in males and females. Absolute risk of MRT in: (A) males and (B) females.
The risk of the myocardial revascularization based on the TyG quartiles in non-diabetic patients.
| Q1 | Q2 | Q3 | Q4 | ||
|
| |||||
| Model 1 | Ref. | 1.25 (1.11, 1.40) | 1.39 (1.23, 1.56) | 1.69 (1.50, 1.90) | <0.001 |
| Model 2 | Ref. | 1.17 (1.03, 1.33) | 1.30 (1.14, 1.47) | 1.55 (1.36, 1.77) | |
|
| |||||
| Model 1 | Ref. | 1.24 (1.08, 1.42) | 1.34 (1.16, 1.54) | 1.65 (1.43, 1.90) | <0.001 |
| Model 2 | Ref. | 1.18 (1.01, 1.37) | 1.28 (1.10, 1.49) | 1.54 (1.31, 1.80) | |
|
| |||||
| Model 1 | Ref. | 1.30 (1.04,1.62) | 1.51 (1.21, 1.89) | 1.71 (1.35, 2.16) | <0.001 |
| Model 2 | Ref. | 1.05 (0.80, 1.36) | 1.28 (0.98, 1.66) | 1.31 (0.99, 1.73) | |
BMI, body mass index; HDL-C, high density lipoprotein cholesterol; PLT, platelets; RBC, red blood cell count; SBP, systolic blood pressure; SUA, serum uric acid; WBC, white blood cell count; TC, total cholesterol.
FIGURE 5The risk of MRT based on TyG index quartiles grouped by SUA quartiles in new-onset ACS patients without diabetes. Adjusted ORs for MRT in: (A) SUA-quartiles 1; (B) SUA-quartiles 2; (C) SUA-quartiles 3; and (D) SUA-quartiles 4. (E) Absolute risk for MRT in each group based on the TyG index quartiles and SUA quartiles.